72324-39-1

Basic information

• Product Name: 5-ACETYL-2,2-DIMETHYL-1,3-DIOXANE-4,6-DIONE
• Synonyms: 5-ACETYL-2,2-DIMETHYL-1,3-DIOXANE-4,6-DIONE;1,3-Dioxane-4,6-dione, 5-acetyl-2,2-diMethyl-
• CAS NO: 72324-39-1
• Molecular Formula: C₈H₁₀O₅
• Molecular Weight: 186.16
• Mol File: 72324-39-1.mol
• Article Data: 14

Chemical Properties

• Melting Point: 83-85°C
• Boiling Point: 417.9 °C at 760 mmHg
• Flash Point: 192.5 °C
• Appearance: /
• Density: 1.231
• Vapor Pressure: 3.42E-07mmHg at 25°C
• Refractive Index: 1.447
• PKA: 8.09±0.40(Predicted)
• CAS DataBase Reference: 5-ACETYL-2,2-DIMETHYL-1,3-DIOXANE-4,6-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ACETYL-2,2-DIMETHYL-1,3-DIOXANE-4,6-DIONE(72324-39-1)
• EPA Substance Registry System: 5-ACETYL-2,2-DIMETHYL-1,3-DIOXANE-4,6-DIONE(72324-39-1)

Safety Data

• Statements: 10
• Safety Statements: 16
• RIDADR: 1224
• HazardClass: IRRITANT
• Hazardous Substances Data: 72324-39-1(Hazardous Substances Data)

Usage

General Description

5-Acetyl-2,2-dimethyl-1,3-dioxane-4,6-dione, also known as acedione, is a chemical compound primarily used as a reagent in organic synthesis. It is a white crystalline solid with a molecular formula of C6H8O4. Acedione is commonly used as a building block in the production of pharmaceuticals, agrochemicals, and other organic compounds. It is also employed as a crosslinking agent in the manufacturing of polymers and as a precursor in the synthesis of heterocycles. Additionally, acedione is known for its ability to inhibit the enzyme glucose oxidase, and it possesses antimicrobial and antioxidant properties. Despite its diverse applications, acedione is known to be a hazardous substance and should be handled with caution to prevent potential health and environmental risks.

InChI:InChI=1/C8H10O5/c1-4(9)5-6(10)12-8(2,3)13-7(5)11/h5H,1-3H3

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 75-36-5 acetyl chloride 
• 64-19-7 acetic acid 

Downstream Products

• 112378-40-2 5-Acetyl-3-isopropyl-2-phenyl-[1,3]oxazinane-4,6-dione 
• 112632-01-6 3-Isopropyl-6-methyl-4-oxo-2-phenyl-3,4-dihydro-2H-[1,3]oxazine-5-carboxylic acid 
• 88091-13-8 (3S,4S)-3-Acetyl-1-isopropyl-4-phenyl-azetidin-2-one 
• 88091-07-0 3-Isopropyl-6-methyl-2-phenyl-2,3-dihydro-[1,3]oxazin-4-one 
• 112378-42-4 5-Acetyl-3-tert-butyl-2-phenyl-[1,3]oxazinane-4,6-dione 
• 81375-57-7 3-acetyl-1-tert-butyl-4-phenyl-2-azetidinone 
• 88091-08-1 3-tert-butyl-3,4-dihydro-6-methyl-2-phenyl-2H-1,3-oxazin-4-one 
• 112378-67-3 3-tert-Butyl-6-methyl-4-oxo-2-phenyl-3,4-dihydro-2H-[1,3]oxazine-5-carboxylic acid 
• 112632-00-5 6-Methyl-4-oxo-2-phenyl-3-propyl-3,4-dihydro-2H-[1,3]oxazine-5-carboxylic acid 
• 88121-68-0 trans-1-Propyl-3-acetyl-4-phenyl-2-azetidinone 
• 81375-55-5 6-Methyl-2-phenyl-3-propyl-2,3-dihydro-[1,3]oxazin-4-one 
• 88091-14-9 5-acetyl-3,4,5,6-tetrahydro-2-phenyl-3-propyl-1,3-oxazine-4,6-dione 
• 61369-33-3 3,4-dihydro-6-methyl-2,3-diphenyl-2H-1,3-oxazin-4-one 
• 112378-47-9 5-Acetyl-2,3-diphenyl-[1,3]oxazinane-4,6-dione 

Relevant articles and documents

Preparation method of tenuazonic Acid and derivative thereof

The invention provides a preparation method of tenuazonic Acid and a derivative thereof. The synthesis route comprises the following steps: reacting malonic acid cycloisopropylidene ester with acyl chloride, then reacting with amino acid methyl ester hydr

5 - N-propyl -4 -hydroxypyrrole -2 - ketone derivative as well as preparation method and application thereof

5 - N-propyl -4 -hydroxypyrro -2 -one derivatives as well as a preparation method and application thereof are disclosed. The 5 -n-propyl -4 -hydroxypyrrole -2 - ketone derivative provided by the invention has a significant improvement in weeding activity

Quinolones modulate ghrelin receptor signaling: Potential for a novel small molecule scaffold in the treatment of cachexia

Cachexia is a metabolic wasting disorder characterized by progressive weight loss, muscle atrophy, fatigue, weakness, and appetite loss. Cachexia is associated with almost all major chronic illnesses including cancer, heart failure, obstructive pulmonary disease, and kidney disease and significantly impedes treatment outcome and therapy tolerance, reducing physical function and increasing mortality. Current cachexia treatments are limited and new pharmacological strategies are needed. Agonists for the growth hormone secretagogue (GHS-R1a), or ghrelin receptor, prospectively regulate the central regulation of appetite and growth hormone secretion, and therefore have tremendous potential as cachexia therapeutics. Non-peptide GHS-R1a agonists are of particular interest, especially given the high gastrointestinal degradation of peptide-based structures, including that of the endogenous ligand, ghrelin, which has a half-life of only 30 min. However, few compounds have been reported in the literature as non-peptide GHS-R1a agonists. In this paper, we investigate the in vitro potential of quinolone compounds to modulate the GHS-R1a in both transfected human cells and mouse hypothalamic cells. These chemically synthesized compounds demonstrate a promising potential as GHS-R1a agonists, shown by an increased intracellular calcium influx. Further studies are now warranted to substantiate and exploit the potential of these novel quinolone-based compounds as orexigenic therapeutics in conditions of cachexia and other metabolic and eating disorders.